0
Original Investigation |

Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease:  The TEAM-AD VA Cooperative Randomized Trial

Maurice W. Dysken, MD1; Mary Sano, PhD2; Sanjay Asthana, MD3; Julia E. Vertrees, PharmD, BCPP4; Muralidhar Pallaki, MD5,6; Maria Llorente, MD7; Susan Love, MA1; Gerard D. Schellenberg, PhD8; J. Riley McCarten, MD1; Julie Malphurs, PhD9; Susana Prieto, MD9; Peijun Chen, MD, MPH, PhD5,6; David J. Loreck, MD10,11; George Trapp, MD, JD12; Rajbir S. Bakshi, MD12; Jacobo E. Mintzer, MD13,14,15; Judith L. Heidebrink, MD16; Ana Vidal-Cardona, MD17; Lillian M. Arroyo, MD17; Angel R. Cruz, MD18; Sally Zachariah, MD18; Neil W. Kowall, MD19; Mohit P. Chopra, MD19; Suzanne Craft, PhD20,21; Stephen Thielke, MD20,21; Carolyn L. Turvey, PhD22,23; Catherine Woodman, MD22,23; Kimberly A. Monnell, MD24; Kimberly Gordon, MSN, RN, FNP-BC24; Julie Tomaska, PhD1; Yoav Segal, MD, PhD1; Peter N. Peduzzi, PhD25,26; Peter D. Guarino, MPH, PhD25,26
[+] Author Affiliations
1Minneapolis VA Health Care System, Minneapolis, Minnesota
2James J. Peters VA Medical Research Center, New York, New York
3William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin
4Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, New Mexico
5Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio
6Case Western Reserve University School of Medicine, Cleveland, Ohio
7Washington DC VA Medical Center, Washington, DC
8University of Pennsylvania School of Medicine, Philadelphia
9Miami VA Healthcare System, Miami, Florida
10VA Maryland Healthcare System, Baltimore
11University of Maryland Medical School, Department of Psychiatry, Baltimore
12VA North Texas Health Care System, Dallas
13Ralph H. Johnson VA Medical Center, Charleston, South Carolina
14Department of Health Studies, Medical University of South Carolina, Charleston
15Roper St Francis Healthcare, Charleston, South Carolina
16VA Ann Arbor Healthcare System, Ann Arbor, Michigan
17VA Caribbean Healthcare System, San Juan, Puerto Rico
18Bay Pines VA Healthcare System, Bay Pines, Florida
19VA Boston Healthcare System, Boston, Massachusetts
20VA Puget Sound Health Care System, Seattle, Washington
21Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle
22Iowa City VA Medical Center, Iowa City, Iowa
23University of Iowa, Iowa City
24W. G. (Bill) Hefner VA Medical Center, Salisbury, North Carolina
25Cooperative Studies Program Coordinating Center, VA Connecticut Healthcare System, West Haven
26Yale University School of Public Health, New Haven, Connecticut
JAMA. 2014;311(1):33-44. doi:10.1001/jama.2013.282834.
Text Size: A A A
Published online

Importance  Although vitamin E and memantine have been shown to have beneficial effects in moderately severe Alzheimer disease (AD), evidence is limited in mild to moderate AD.

Objective  To determine if vitamin E (alpha tocopherol), memantine, or both slow progression of mild to moderate AD in patients taking an acetylcholinesterase inhibitor.

Design, Setting, and Participants  Double-blind, placebo-controlled, parallel-group, randomized clinical trial involving 613 patients with mild to moderate AD initiated in August 2007 and concluded in September 2012 at 14 Veterans Affairs medical centers.

Interventions  Participants received either 2000 IU/d of alpha tocopherol (n = 152), 20 mg/d of memantine (n = 155), the combination (n = 154), or placebo (n = 152).

Main Outcomes and Measures  Alzheimer’s Disease Cooperative Study/Activities of Daily Living (ADCS-ADL) Inventory score (range, 0-78). Secondary outcomes included cognitive, neuropsychiatric, functional, and caregiver measures.

Results  Data from 561 participants were analyzed (alpha tocopherol = 140, memantine = 142, combination = 139, placebo = 140), with 52 excluded because of a lack of any follow-up data. Over the mean (SD) follow-up of 2.27 (1.22) years, ADCS-ADL Inventory scores declined by 3.15 units (95% CI, 0.92 to 5.39; adjusted P = .03) less in the alpha tocopherol group compared with the placebo group. In the memantine group, these scores declined 1.98 units less (95% CI, −0.24 to 4.20; adjusted P = .40) than the placebo group’s decline. This change in the alpha tocopherol group translates into a delay in clinical progression of 19% per year compared with placebo or a delay of approximately 6.2 months over the follow-up period. Caregiver time increased least in the alpha tocopherol group. All-cause mortality and safety analyses showed a difference only on the serious adverse event of “infections or infestations,” with greater frequencies in the memantine (31 events in 23 participants) and combination groups (44 events in 31 participants) compared with placebo (13 events in 11 participants).

Conclusions and Relevance  Among patients with mild to moderate AD, 2000 IU/d of alpha tocopherol compared with placebo resulted in slower functional decline. There were no significant differences in the groups receiving memantine alone or memantine plus alpha tocopherol. These findings suggest benefit of alpha tocopherol in mild to moderate AD by slowing functional decline and decreasing caregiver burden.

Trial Registration  clinicaltrials.gov Identifier: NCT00235716

Figures in this Article

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

Figures

Place holder to copy figure label and caption
Figure 1.
Flow of Participants in the Study
Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Changes in Primary Outcome (ADCS-ADL Inventory Score) During the 4-Year Study Period, Compared With Baseline

In this between-group comparison, lower scores indicate worse functioning. Data are least squares means at each time point. Values have been adjusted for baseline scores as a fixed effect and the study site as a random effect. ADCS-ADL indicates Alzheimer’s Disease Cooperative Study/Activities of Daily Living; error bars, 95% CIs.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.
Changes in 4 Secondary Outcomes During the 4-Year Study Period, Compared With Baseline

Data are least squares means at each time point. Values have been adjusted for baseline scores as a fixed effect and the study site as a random effect. For between-group comparisons of scores on the the Mini-Mental State Examination (MMSE) (A), lower scores indicate worse functioning. For comparisons of the Alzheimer Disease Assessment Scale–Cognitive portion (ADAS-cog) (B), Neuropsychiatric Inventory (C), and the Caregiver Activity Survey (D), higher scores indicate worse functioning. Error bars indicate 95% CIs.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 4.
Dependence Scale Score Time-to-Event Analysis

The Dependence Scale assesses 6 levels of functional dependence. Time to event is the time to loss of 1 dependence level (increase in dependence). We used an interval-censored model assuming a Weibull distribution because the time of the event was known only at the end of a discrete interval of time (every 6 months).

Graphic Jump Location

Tables

References

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 1

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Multimedia Related by Topic

Author Interview

Articles Related By Topic
Related Topics
PubMed Articles
Jobs
JAMAevidence.com

Users' Guides to the Medical Literature
Table 9.2-3 Refuted Evidence From Observational Studiesa

brightcove.createExperiences();